Company Overview

Grifols, S.A. is a global healthcare company headquartered in Spain, specializing in the development, production, and commercialization of plasma-derived medicines, transfusion medicine solutions, and diagnostic systems. The company operates primarily in the biopharmaceuticals and medical technology industries, with a strong focus on therapies derived from human plasma used to treat rare, chronic, and life‑threatening conditions.

Grifols’ core revenue is driven by its plasma-derived therapies, particularly immunoglobulins, albumin, and alpha-1 antitrypsin, serving hospitals, clinics, and healthcare systems worldwide. A key strategic advantage is its vertically integrated plasma supply chain, including one of the world’s largest networks of plasma collection centers. Founded in 1940 as a family-owned clinical laboratory, Grifols evolved into a multinational company through sustained investment in plasma science, manufacturing scale, and global expansion, becoming a publicly traded company in 2006.

Business Operations

Grifols organizes its activities into several primary operating segments, including Bioscience, Diagnostic, Hospital, and Bio Supplies. The Bioscience segment represents the majority of revenue and encompasses plasma-derived products and plasma collection operations, generating income through long-term supply agreements and product sales to healthcare providers. The Diagnostic segment develops and markets in vitro diagnostic systems, reagents, and instruments used in blood screening and clinical diagnostics.

Operations are conducted across both domestic and international markets, with significant infrastructure in North America, Europe, and Asia-Pacific. Grifols controls extensive plasma collection assets, fractionation plants, and R&D facilities, supported by proprietary manufacturing technologies. Key subsidiaries include Grifols Biologicals LLC, Biotest AG, and Grifols Diagnostic Solutions Inc., which support specialized production, research, and regional market access.

Strategic Position & Investments

Grifols’ strategy emphasizes organic growth in plasma-derived therapies, operational efficiency, and balance sheet stabilization following a period of elevated leverage. Growth initiatives focus on increasing plasma collection capacity, expanding immunoglobulin production, and advancing next-generation plasma therapies. The company has also prioritized cost optimization and capital discipline while maintaining investment in critical R&D programs.

Notable strategic investments include the acquisition of Biotest AG, which expanded Grifols’ product portfolio and manufacturing capabilities in Europe, and ongoing investments in plasma center expansion in the United States. Grifols is also involved in emerging areas such as hyperimmune globulins and novel biologics derived from plasma proteins, positioning the company to address unmet medical needs in immunology and critical care.

Geographic Footprint

Grifols maintains a global operating presence, with its corporate headquarters in Barcelona, Spain, and major operational centers in the United States, Germany, and the United Kingdom. The company has a particularly strong footprint in North America, which represents its largest market and the core of its plasma collection network.

Commercial and manufacturing operations extend across Europe, Asia-Pacific, Latin America, and parts of Africa, allowing Grifols to supply products in over 100 countries. Its international reach is supported by regional subsidiaries, distribution partnerships, and long-term supply contracts with national healthcare systems, giving the company significant global influence in plasma-derived therapeutics.

Leadership & Governance

Grifols maintains a governance structure that reflects its origins as a family-founded company while operating under public market standards. Strategic leadership emphasizes long-term investment in scientific innovation, operational integration, and patient-centric healthcare solutions. The company’s leadership philosophy centers on vertical integration, medical specialization, and global scale.

Key executives include:

• Thomas Glanzmann – Executive Chairman
• Nacho Abia – Chief Executive Officer
• Víctor Grífols Deu – Co-Chief Executive Officer
• Raimon Grifols Roura – Chief Corporate Officer
• Fabián Alegría – Chief Financial Officer

The Grifols family continues to hold a significant ownership stake, contributing to continuity in strategic vision and long-term decision-making.